Authored by Karl Simpson
Polyphor is a company nestled in the BioValley, Switzerland and is focused on the research and development of macrocyclic drugs. The company’s drug discovery technology platform has enabled them to build a pipeline of drug candidates aimed at bringing new and innovative therapies to market. The candidates are now progressing towards a clinical stage, with POL6326, a CXCR4 antagonist with upcoming and ongoing phase II clinical trials for stem cell transplantation, tissue repair and combination treatments in cancer. Polyphor also has other assets, POL7080 a highly specific antibiotic and POL6014 an inhibitor of neutrophil elastase for the treatment of Alpha Antitryspin Deficiency, Cystic Fibrosis, and other lung diseases by inhalation.
Earlier this month, Polyphor announced significant additions to its team as it appointed key people to the Board of the company. These are key additions bringing substantial experience to the Board from two of the big pharmaceutical neighbours, Novartis and Roche. Jerry Karabelas was the CEO of Worldwide Pharmaceutical, head of all three healthcare businesses and a member of the executive committee at Novartis AG. Whereas, Jean-Jacques Garaud served until 2012 as Head of Roche Pharma Research and Early Development and a member of the Enlarged Roche Corporate Executive Committee. Jerry Karabelas will serve as Chairman of the Board.
These appointments to the Board were part of a transition as existing members of the board leave and as Polyphor progress their drug candidates in the clinical phase towards successful marketing authorisation and commercialisation, part of their broader strategy towards becoming a fully integrated pharmaceutical company.